Article

2025

Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia

Projected Lifetime CancerRisksFrom CurrentComputedTomographyImaging

NHS first in world to roll out ‘revolutionary’ blood test for cancer patients

Trimar Strategies – Lung Consenses Statement

Advancing the Implementation of Risk Model- Based Lung Cancer Screening

Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer

2024

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

2023

Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country

Mutational Profiling of Lung Cancer Using Next Generation Sequencing: A Malaysian Real-World Clinical Diagnostic Experience

2022

Consensus statement on the potential role of Artificial Intelligence-assisted Chest X-ray in identifying early lung cancer patients in Malaysia

Consensus Statement on Molecular Testing for Advanced Non-Small Cell Lung Cancer in Malaysia (2019 Edition)

2021

Qure.ai secures partnerships that will use its AI-powered solution for disease screening

2019

DURVALUMAB ENTERS THE FRAY IN FIGHT AGAINST LUNG CANCER

Malaysia Fact Sheets

Lung cancer diagnosis and management

2018

WCLC Press Program Press Release De Koning

Malaysian Study on Cancer Survival

2017

Durvalumab after Chemoradiotherapy in Stage III Non Small Cell Lung Cancer

Summary of Malaysian National Cancer Registry Report 2007-2011

2012

Computed tomography surveillance of lung cancer survivors

Screening for Lung Cancer

2011

Reduced Lung-Cancer Mortality with Low-Dose CT Screening

X